Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Short term Debt (2022 - 2025)

Historic Short term Debt for BioXcel Therapeutics (BTAI) over the last 3 years, with Q3 2025 value amounting to $16.8 million.

  • BioXcel Therapeutics' Short term Debt changed N/A to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year change of. This contributed to the annual value of $422000.0 for FY2022, which is N/A changed from last year.
  • Per BioXcel Therapeutics' latest filing, its Short term Debt stood at $16.8 million for Q3 2025.
  • BioXcel Therapeutics' 5-year Short term Debt high stood at $16.8 million for Q3 2025, and its period low was $56000.0 during Q1 2022.
  • For the 3-year period, BioXcel Therapeutics' Short term Debt averaged around $3.7 million, with its median value being $576000.0 (2022).
  • The largest annual percentage gain for BioXcel Therapeutics' Short term Debt in the last 5 years was 57857.14% (2023), contrasted with its biggest fall of 17137.55% (2023).
  • Over the past 3 years, BioXcel Therapeutics' Short term Debt (Quarter) stood at $422000.0 in 2022, then soared by 72.99% to $730000.0 in 2023, then soared by 2204.52% to $16.8 million in 2025.
  • Its Short term Debt stands at $16.8 million for Q3 2025, versus $11.2 million for Q2 2025 and $5.6 million for Q1 2025.